secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acrivon Therapeutics, Inc. (ACRV)
CIK:        0001781174
Form:       8-K
Filed at:   2026-03-02T23:59:59+00:00
Accession:  0001193125-26-085516
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

Acrivon terminates Akoya/Quanterix diagnostic deal; opens internal CLIA lab
---------------------------------------------------------------------------

- Mutually terminated OncoSignature Companion Diagnostic Agreement with Akoya (Quanterix) effective Feb 25, 2026.
- No financial payments between the parties for termination; transition plan transfers testing procedures and materials to Acrivon.
- Acrivon has completed and certified its own internal CLIA laboratory in Watertown, MA.
- Acrivon now has full development and commercialization rights to its proprietary ACR-368 OncoSignature test.
- Quanterix will continue to support ACR-368 clinical testing for Acrivon's ongoing Phase 2b study during the transition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781174/000119312526085516/0001193125-26-085516-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781174/000119312526085516/d111455d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-085516

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer